A citation-based method for searching scientific literature

Yao-Hui Huang, Kun Cai, Peng-Peng Xu, Li Wang, Chuan-Xin Huang, Ying Fang, Shu Cheng, Xiao-Jian Sun, Feng Liu, Jin-Yan Huang, Meng-Meng Ji, Wei-Li Zhao. Signal Transduct Target Ther 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci, Luca Mazzarella. J Immunother Cancer 2019
81
50

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Zijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu, Ganiraju C Manyam, Louise Kristensen, Lei Fan, Carlo Visco, Karen Dybkaer,[...]. Blood 2013
36
50

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos,[...]. Blood 2019
92
50


Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang, Qi Zhao, Ming-Ming He, Ying-Nan Wang, Feng Wang, Rui-Hua Xu. J Immunother Cancer 2019
23
50

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Samra Turajlic, Kevin Litchfield, Hang Xu, Rachel Rosenthal, Nicholas McGranahan, James L Reading, Yien Ning S Wong, Andrew Rowan, Nnennaya Kanu, Maise Al Bakir,[...]. Lancet Oncol 2017
372
50

Rituximab: mechanism of action.
George J Weiner. Semin Hematol 2010
438
50

Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.
Stefano Monti, Bjoern Chapuy, Kunihiko Takeyama, Scott J Rodig, Yansheng Hao, Kelly T Yeda, Haig Inguilizian, Craig Mermel, Treeve Currie, Ahmet Dogan,[...]. Cancer Cell 2012
128
50

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Yunfei Shi, Youming Lei, Li Liu, Shiyue Zhang, Wenjing Wang, Juan Zhao, Songhui Zhao, Xiaowei Dong, Ming Yao, Kai Wang,[...]. Cancer Med 2021
4
50

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Zijun Y Xu-Monette, Jianyong Li, Yi Xia, Beryl Crossley, Robert D Bremel, Yi Miao, Min Xiao, Thomas Snyder, Ganiraju C Manyam, Xiaohong Tan,[...]. J Immunother Cancer 2019
6
50

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
50

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
Cristina Valero, Mark Lee, Douglas Hoen, Kate Weiss, Daniel W Kelly, Prasad S Adusumilli, Paul K Paik, George Plitas, Marc Ladanyi, Michael A Postow,[...]. Nat Commun 2021
10
50

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Zijun Y Xu-Monette, Jianfeng Zhou, Ken H Young. Blood 2018
159
50

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Zhijie Wang, Jianchun Duan, Shangli Cai, Miao Han, Hua Dong, Jun Zhao, Bo Zhu, Shuhang Wang, Minglei Zhuo, Jianguo Sun,[...]. JAMA Oncol 2019
163
50

Significance analysis of microarrays applied to the ionizing radiation response.
V G Tusher, R Tibshirani, G Chu. Proc Natl Acad Sci U S A 2001
50

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
447
50

Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
Kirsty Wienand, Bjoern Chapuy, Chip Stewart, Andrew J Dunford, David Wu, Jaegil Kim, Atanas Kamburov, Timothy R Wood, Fathima Zumla Cader, Matthew D Ducar,[...]. Blood Adv 2019
24
50

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Jianfeng Shen, Zhenlin Ju, Wei Zhao, Lulu Wang, Yang Peng, Zhongqi Ge, Zachary D Nagel, Jun Zou, Chen Wang, Prabodh Kapoor,[...]. Nat Med 2018
165
50

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
Yi Miao, L Jeffrey Medeiros, Zijun Y Xu-Monette, Jianyong Li, Ken H Young. Front Oncol 2019
18
50

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Zijun Y Xu-Monette, Lin Wu, Carlo Visco, Yu Chuan Tai, Alexander Tzankov, Wei-min Liu, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, Attilio Orazi,[...]. Blood 2012
195
50

KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Fatemeh Ardeshir-Larijani, Priyanka Bhateja, Mary Beth Lipka, Neelesh Sharma, Pingfu Fu, Afshin Dowlati. Clin Lung Cancer 2018
18
50


PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young. Front Immunol 2017
117
50

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Alexandar Tzankov, Zijun Y Xu-Monette, Marc Gerhard, Carlo Visco, Stephan Dirnhofer, Nora Gisin, Karen Dybkaer, Attilio Orazi, Govind Bhagat, Kristy L Richards,[...]. Mod Pathol 2014
90
50

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Ziju Y Xu-Monette, Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, Raul Torres-Ruiz, Ganiraju C Manyam, Carlo Visco,[...]. Cancer Immunol Res 2019
38
50

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.
Jillian F Wise, Sigve Nakken, Chloé B Steen, Daniel Vodák, Gunhild Trøen, Bjarne Johannessen, Ole Christian Lingjærde, Vera Hilden, Yngvild Nuvin Blaker, Baoyan Bai,[...]. Blood Adv 2020
4
50


Identifying biological themes within lists of genes with EASE.
Douglas A Hosack, Glynn Dennis, Brad T Sherman, H Clifford Lane, Richard A Lempicki. Genome Biol 2003
50

H3K4 methylation at active genes mitigates transcription-replication conflicts during replication stress.
Shin Yen Chong, Sam Cutler, Jing-Jer Lin, Cheng-Hung Tsai, Huai-Kuang Tsai, Sue Biggins, Toshio Tsukiyama, Yi-Chen Lo, Cheng-Fu Kao. Nat Commun 2020
8
50

1
100

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Philippe Armand, Yi-Bin Chen, Robert A Redd, Robin M Joyce, Jad Bsat, Erin Jeter, Reid W Merryman, Kimberly C Coleman, Parastoo B Dahi, Yago Nieto,[...]. Blood 2019
51
50

Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
Madhavi Challa-Malladi, Yen K Lieu, Olivia Califano, Antony B Holmes, Govind Bhagat, Vundavalli V Murty, David Dominguez-Sola, Laura Pasqualucci, Riccardo Dalla-Favera. Cancer Cell 2011
247
50

Genetic alterations and their clinical implications in DLBCL.
Yi Miao, L Jeffrey Medeiros, Yong Li, Jianyong Li, Ken H Young. Nat Rev Clin Oncol 2019
41
50

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
601
50

Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Manman Deng, Zijun Y Xu-Monette, Lan V Pham, Xudong Wang, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkaer,[...]. Mol Cancer Res 2021
2
50

Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Laura Pasqualucci, David Dominguez-Sola, Annalisa Chiarenza, Giulia Fabbri, Adina Grunn, Vladimir Trifonov, Lawryn H Kasper, Stephanie Lerach, Hongyan Tang, Jing Ma,[...]. Nature 2011
567
50


Cluster analysis and display of genome-wide expression patterns.
M B Eisen, P T Spellman, P O Brown, D Botstein. Proc Natl Acad Sci U S A 1998
50

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy,[...]. J Clin Oncol 2019
110
50

Epigenetic mechanisms and genome stability.
Emily L Putiri, Keith D Robertson. Clin Epigenetics 2011
58
50

The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Ana Ortega-Molina, Isaac W Boss, Andres Canela, Heng Pan, Yanwen Jiang, Chunying Zhao, Man Jiang, Deqing Hu, Xabier Agirre, Itamar Niesvizky,[...]. Nat Med 2015
197
50

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.
Ryosuke Okamura, Shumei Kato, Suzanna Lee, Rebecca E Jimenez, Jason K Sicklick, Razelle Kurzrock. J Immunother Cancer 2020
31
50

Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas.
D Pérez-Callejo, J González-Rincón, A Sánchez, M Provencio, M Sánchez-Beato. Cancer Treat Rev 2015
29
50

Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov, Kristian Cibulskis, Andrey Sivachenko, Scott L Carter, Chip Stewart, Craig H Mermel, Steven A Roberts,[...]. Nature 2013
50

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers.
Hao-Xiang Wu, Zi-Xian Wang, Qi Zhao, Dong-Liang Chen, Ming-Ming He, Lu-Ping Yang, Ying-Nan Wang, Ying Jin, Chao Ren, Hui-Yan Luo,[...]. Ann Transl Med 2019
21
50

CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Guangchuan Wang, Ryan D Chow, Lvyun Zhu, Zhigang Bai, Lupeng Ye, Feifei Zhang, Paul A Renauer, Matthew B Dong, Xiaoyun Dai, Xiaoya Zhang,[...]. Cancer Discov 2020
8
50

Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Jiyuan Zhang, David Dominguez-Sola, Shafinaz Hussein, Ji-Eun Lee, Antony B Holmes, Mukesh Bansal, Sofija Vlasevska, Tongwei Mo, Hongyan Tang, Katia Basso,[...]. Nat Med 2015
207
50

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.
Li Wang, Jialin Qu, Na Zhou, Helei Hou, Man Jiang, Xiaochun Zhang. Biomed Pharmacother 2020
1
100

Remodelling the extracellular matrix in development and disease.
Caroline Bonnans, Jonathan Chou, Zena Werb. Nat Rev Mol Cell Biol 2014
50

NK Cell Metabolism and Tumor Microenvironment.
Iñigo Terrén, Ane Orrantia, Joana Vitallé, Olatz Zenarruzabeitia, Francisco Borrego. Front Immunol 2019
53
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.